AGER and early-onset autosomal dominant Alzheimer disease: Binding of AGEs to sRAGE, in contrast to interactions with membrane form of RAGE, does not result in inflammatory signal transduction therefore sRAGE acts as inhibitor of RAGE-AGE signaling and is potentially applicable for the treatment of various AGE-related diseases including diabetic cardiovascular complications [92,93], diabetic kidney disease [94] and a number of aging-related diseases including atherosclerosis, cataracts, Alzheimer’s disease and Parkinson’s disease [95,96].